Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma

Head and Neck

Volumn 37, Issue 8, 2015, Pages 1088-1095

  Malm, Ian James ^a,b   Bruno, Tullia C ^b   Fu, Juan ^a   Zeng, Qi ^a   Taube, Janis M ^c   Westra, William ^c   Pardoll, Drew ^b   Drake, Charles G ^b   Kim, Young J ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

anergy; head and neck squamous cell carcinoma (HNSCC); immunotherapy; programmed death 1 (PD 1); T cell

Indexed keywords

INTERLEUKIN 2; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; CD4 ANTIGEN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; WART VIRUS; CARCINOMA, SQUAMOUS CELL; GENETICS; HEAD AND NECK NEOPLASMS; IMMUNOLOGY; PAPILLOMAVIRIDAE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; SENSITIVITY AND SPECIFICITY; TUMOR CELL CULTURE; VIROLOGY;

ANTIGENS, CD274; ANTIGENS, CD4; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; HEAD AND NECK NEOPLASMS; HUMANS; IN VITRO TECHNIQUES; PAPILLOMAVIRIDAE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGRAMMED CELL DEATH 1 RECEPTOR; SENSITIVITY AND SPECIFICITY; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84948564453     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23706     Document Type: Article

References (22)

1. Pulte D, Brenner H,. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010; 15: 994-1001.
2. Davidson HC, Leibowitz MS, Lopez-Albaitero A, Ferris RL,. Immunotherapy for head and neck cancer. Oral Oncol 2009; 45: 747-751.
3. Dougan M, Dranoff G,. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117.
4. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
5. Drake CG, Jaffee E, Pardoll DM,. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
6. Weber J,. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37: 430-439.
7. Topalian SL, Drake CG, Pardoll DM,. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207-212.
8. Strome SE, Dong H, Tamura H, et al., B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501-6505.
9. Brahmer JR, Drake CG, Wollner I, et al., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
10. Brahmer JR, Tykodi SS, Chow LQ, et al., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
11. Wolchok JD, Kluger H, Callahan MK, et al., Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133.
12. Taube JM, Anders RA, Young GD, et al., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra137.
13. Lyford-Pike S, Peng S, Young GD, et al., Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1733-1741.
14. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
15. Weinstein GS, O'Malley BW Jr, Magnuson JS, et al., Transoral robotic surgery: a multicenter study to assess feasibility, safety, and surgical margins. Laryngoscope 2012; 122: 1701-1707.
16. Barber DL, Wherry EJ, Masopust D, et al., Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
17. Ha SJ, Mueller SN, Wherry EJ, et al., Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008; 205: 543-555.
18. Blackburn SD, Shin H, Haining WN, et al., Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009; 10: 29-37.
19. Fourcade J, Sun Z, Benallaoua M, et al., Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-2186.
20. Topalian SL, Hodi FS, Brahmer JR, et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
21. Hodi FS, O'Day SJ, McDermott DF, et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
22. Parsa AT, Waldron JS, Panner A, et al., Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84-88.